Health Care & Life Sciences » Pharmaceuticals | Kyowa Hakko Kirin Co. Ltd.

Kyowa Hakko Kirin Co. Ltd. | Cash Flow

Fiscal year is January-December. All values JPY Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
49,773
27,245
41,400
42,877
55,849
73,438
Depreciation, Depletion & Amortization
33,169
36,711
36,559
23,784
22,032
22,221
Other Funds
155
20
198
533
436
27,034
Funds from Operations
60,128
35,762
65,861
60,937
67,554
68,625
Changes in Working Capital
3,244
16,385
665
5,944
2,652
12,444
Net Operating Cash Flow
56,884
19,377
66,526
66,881
64,902
56,181
Capital Expenditures
34,725
34,652
20,096
30,097
22,334
Sale of Fixed Assets & Businesses
1,748
186
3,080
4,792
8,320
Purchase/Sale of Investments
2,574
2,170
14,420
6,000
3,450
Net Investing Cash Flow
77,163
16,805
57,747
49,824
45,265
Cash Dividends Paid - Total
12,310
13,683
13,682
13,681
13,682
Issuance/Reduction of Debt, Net
12
23,405
52
343
4,169
Net Financing Cash Flow
12,579
37,184
14,060
13,871
18,287
Net Change in Cash
31,091
2,228
4,228
291
2,684
Free Cash Flow
35,285
11,089
47,468
46,186
50,137
Net Assets from Acquisitions
-
14,510
-
-
-
Other Sources
-
67,951
-
813
1,397
Change in Capital Stock
126
116
232
-
-
Exchange Rate Effect
1,767
1,226
1,053
2,895
1,334
Other Uses
46,760
-
55,151
19,332
29,199

About Kyowa Hakko Kirin Co.

View Profile
Address
Otemachi Financial City Grand Cube
Tokyo Tokyo 100
Japan
Employees -
Website http://www.kyowa-kirin.co.jp
Updated 07/08/2019
Kyowa Hakko Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It operates through the Pharmaceuticals and Bio-Chemicals segments. The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension.